Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy

NCT07327905 | Recruiting

• 1 other identifier: 0109246
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression

Conditions

Bariatric Surgery; Lidocaine; Dexmedetomidine

Keywords

lidocaine; dexmedetomidine; bariatric

Outcome Measures

Primary Outcomes (1)

• visual analogue scale

  at rest , movement

  postoperative day 1

Secondary Outcomes (4)

• time to first nalbuphine dose

  postoperative day 1

• patient satisfaction

  postoperative day1

• postoperative nalbuphine requirements

  postoperative day 1

• postoperative complications

  postoperative day 1

Study Arms (2)

group L

ACTIVE COMPARATOR

receive lidocaine infusion

Other: intravenous lidocaine

group D

ACTIVE COMPARATOR

receive dexmedetomidine infusion

Other: intravenous dexmedetomidine

Interventions

intravenous lidocaine OTHER

20 patients will receive lidocaine infusion

Also known as: group L

group L

intravenous dexmedetomidine OTHER

20 patients will receive dexmedetomidine infusion

Also known as: group D

group D

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age: 20-50 years, both sexes.
• American Standards Association (ASA) physical status class II to III.
• Body mass index (BMI) 35-50 kg m-².

You may not qualify if:

• Cardiac conduction disorders.
• Cardiomyopathy.
• Chronic opioid use.
• Allergy to the studied medications.
• Pregnancy and breastfeeding.

Sponsors & Collaborators

• Alexandria University: lead

Study Sites (1)

Alexandria University

Alexandria, Egypt

RECRUITING

Related Publications (1)

• Singh V, Pahade A, Mowar A. Comparing Efficacy of Intravenous Dexmedetomidine and Lidocaine on Perioperative Analgesic Consumption in Patients Undergoing Laparoscopic Surgery. Anesth Essays Res. 2022 Jul-Sep;16(3):353-359. doi: 10.4103/aer.aer_121_22. Epub 2022 Dec 9.

  PMID: 36620103 BACKGROUND

Study Officials

• sarah m elgamal, MD

  Alexandria University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

sarah m elgamal, MD

CONTACT

01005496440; sarahelgamal1990@yahoo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer

Study Record Dates

• First Submitted: December 26, 2025
• First Posted: January 8, 2026
• Study Start: December 26, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: January 8, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)